{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:10:34Z","timestamp":1793211034327,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.expneurol.2013.09.014","type":"journal-article","created":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T14:45:28Z","timestamp":1379947528000},"page":"133-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Modeling Parkinson's disease in monkeys for translational studies, a critical analysis"],"prefix":"10.1016","volume":"256","author":[{"given":"Lisa F.","family":"Potts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marcilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Luquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2013.09.014_bb0005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0014-2999(87)90277-9","article-title":"Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat","volume":"141","author":"Algeri","year":"1987","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-4274(88)90122-1","article-title":"Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina and caudate nucleus of the cat","volume":"44","author":"Ambrosio","year":"1988","journal-title":"Toxicol. Lett."},{"issue":"3","key":"10.1016\/j.expneurol.2013.09.014_bb0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pharmthera.2011.07.004","article-title":"Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease","volume":"132","author":"Armentero","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0024-3205(86)90431-5","article-title":"Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"39","author":"Bankiewicz","year":"1986","journal-title":"Life Sci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0025","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.expneurol.2009.07.019","article-title":"Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model","volume":"219","author":"Barraud","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0035","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/mds.23696","article-title":"A tale on animal models of Parkinson's disease","volume":"26","author":"Bezard","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0030","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.expneurol.2004.11.013","article-title":"Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates","volume":"192","author":"Bibbiani","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0022-510X(90)90225-C","article-title":"The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease","volume":"97","author":"Bloem","year":"1990","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0050","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","article-title":"A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"80","author":"Burns","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0055","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(08)60489-4","article-title":"Contributions of non-human primates to neuroscience research","volume":"371","author":"Capitanio","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0060","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2982.2008.01226.x","article-title":"Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism","volume":"21","author":"Chaumette","year":"2009","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0070","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0014-4886(03)00246-2","article-title":"Primate models of Parkinson's disease","volume":"183","author":"Collier","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0075","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.expneurol.2013.09.014_bb0080","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0091-3057(91)90603-Y","article-title":"Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist","volume":"38","author":"Eden","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0090","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0306-4522(86)90102-8","article-title":"Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys","volume":"18","author":"Eidelberg","year":"1986","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0306-4522(99)00437-6","article-title":"Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment","volume":"95","author":"Elsworth","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ilar.48.4.339","article-title":"Nonhuman primate models of Parkinson's disease","volume":"48","author":"Emborg","year":"2007","journal-title":"ILAR J."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","article-title":"Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial","volume":"16","author":"Fernandez","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0149-7634(96)00042-5","article-title":"Species differences in the role of excitatory amino acids in experimental parkinsonism","volume":"21","author":"Fornai","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ana.410200403","article-title":"Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys","volume":"20","author":"Forno","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0115","first-page":"600","article-title":"Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations","volume":"60","author":"Forno","year":"1993","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0079-6123(10)84007-5","article-title":"The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future","volume":"184","author":"Fox","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mds.870040109","article-title":"The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"4","author":"Gibb","year":"1989","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0014-2999(01)00737-3","article-title":"Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys","volume":"412","author":"Hadj Tahar","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0140","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00702-011-0698-2","article-title":"Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation","volume":"118","author":"Iravani","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0145","first-page":"497","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates","volume":"54","author":"Jakowec","year":"2004","journal-title":"Comp. Med."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0150","first-page":"S90","article-title":"Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates","volume":"47","author":"Jenner","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0155","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.61.6_suppl_3.S4","article-title":"The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0024-3205(85)90062-1","article-title":"Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects","volume":"36","author":"Johannessen","year":"1985","journal-title":"Life Sci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0170","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0175","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0180","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0185","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1523\/JNEUROSCI.1176-08.2008","article-title":"Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements","volume":"28","author":"Liang","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0190","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ana.410310514","article-title":"Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys","volume":"31","author":"Luquin","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0195","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0896-6273(00)80733-3","article-title":"Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen","volume":"22","author":"Luquin","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.expneurol.2005.11.002","article-title":"Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?","volume":"197","author":"Marin","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0205","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.expneurol.2013.01.024","article-title":"Modeling dyskinesia in animal models of Parkinson disease","volume":"256","author":"Morin","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0210","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/brain\/awm208","article-title":"A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery","volume":"130","author":"Mounayar","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0215","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ana.21832","article-title":"Modeling Parkinson's disease","volume":"66","author":"Olanow","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0220","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1523\/JNEUROSCI.22-12-04942.2002","article-title":"Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration","volume":"22","author":"Palfi","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0290","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","article-title":"Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration","volume":"662","author":"Papa","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0230","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1046\/j.1471-4159.2001.00183.x","article-title":"The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety","volume":"76","author":"Przedborski","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0235","series-title":"R: A Language and Environment for Statistical Computing","author":"R, D.C.T.","year":"2011"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0240","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0245","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0006-8993(93)90049-S","article-title":"Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys","volume":"615","author":"Schneider","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0255","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0022-3565(24)34957-2","article-title":"Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys","volume":"290","author":"Schneider","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0250","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbr.2010.03.040","article-title":"Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism","volume":"211","author":"Schneider","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0260","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1523\/JNEUROSCI.20-13-05102.2000","article-title":"Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting","volume":"20","author":"Song","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0265","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.expneurol.2009.07.011","article-title":"Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction","volume":"219","author":"Stockwell","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0270","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0306-4522(97)00214-5","article-title":"Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)","volume":"81","author":"Taylor","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0275","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/NEN.0b013e3181b35e41","article-title":"Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys","volume":"68","author":"Vazquez-Claverie","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.09.014_bb0280","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/0306-4522(87)90178-3","article-title":"An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset","volume":"23","author":"Waters","year":"1987","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.09.014_bb0285","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488613002823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488613002823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T14:50:35Z","timestamp":1746024635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488613002823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":58,"alternative-id":["S0014488613002823"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2013.09.014","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling Parkinson's disease in monkeys for translational studies, a critical analysis","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2013.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}